• LAST PRICE
    1.5700
  • TODAY'S CHANGE (%)
    Trending Down-0.0100 (-0.6329%)
  • Bid / Lots
    1.5500/ 6
  • Ask / Lots
    1.5900/ 5
  • Open / Previous Close
    1.5600 / 1.5800
  • Day Range
    Low 1.5524
    High 1.6000
  • 52 Week Range
    Low 1.3750
    High 5.3500
  • Volume
    5,967
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 1.58
TimeVolumeCMMB
09:43 ET10001.56
09:54 ET3001.6
10:08 ET4671.56
10:10 ET2771.563
10:24 ET1001.6
10:32 ET1001.56
10:55 ET2501.5685
11:40 ET1301.5524
12:00 ET1001.5524
01:57 ET1001.56
03:41 ET1901.56
03:43 ET2001.56
03:52 ET6181.59
03:57 ET4671.57
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCMMB
Chemomab Therapeutics Ltd
17.5M
0.0x
---
United StatesKZIA
Kazia Therapeutics Ltd
26.1M
-1.0x
---
United StatesNRSN
Neurosense Therapeutics Ltd
18.0M
-1.5x
---
United StatesTNXP
Tonix Pharmaceuticals Holding Corp
16.9M
-0.1x
---
United StatesZYNE
Zynerba Pharmaceuticals Inc
16.6M
-0.4x
---
United StatesEVLO
Evelo Biosciences Inc
16.6M
-0.1x
---
As of 2023-05-31

Company Information

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Contact Information

Headquarters
Kiryat Atidim, Building 7TEL AVIV-YAFO, Israel 6158002
Phone
---
Fax
---

Executives

Chairman of the Board, Chief Executive Officer
Dale Pfost
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Donald Marvin
Chief Executive Officer, Chief Scientific Officer, Director
Adi Mor
Chief Medical Officer, Vice President - Drug Development
Matthew Frankel
Independent Director
Neil Cohen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$17.5M
Revenue (TTM)
$0.00
Shares Outstanding
11.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.35
EPS
$-44.41
Book Value
$49.83
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.